Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Comparative analysis of the clinical outcomes of multifocal intraocular lenses with different add powers

Search Title by author or title

Session Details

Session Title: Pseudophakic IOLs: Multifocal II

Session Date/Time: Tuesday 13/09/2016 | 08:00-10:30

Paper Time: 08:18

Venue: Auditorium C6

First Author: : J.Lee SOUTH KOREA

Co Author(s): :    J. Lee   Y. Park   J. Lee   H. Choi           

Abstract Details

Purpose:

To compare the clinical outcomes of multifocal intraocular lenses(IOLs) with different add powers after cataract surgery.

Setting:

Pusan National University Yangsan Hospital.

Methods:

Consecutive eyes of cataract patients were divided into 2 groups. Group A received a Tecnis multifocal IOL with a near add power of +2.75 diopters (D) and Group B, with a near add power of +4.00 D. Distance, near, and intermediate visual acuity outcomes were evaluated during a 6-month follow-up. Postoperative contrast sensitivity, ocular aberrations, defocus curves, and patient satisfaction were analyzed.

Results:

Patients ranged in age from 41 to 62 years. Group A comprised 15 eyes and Group B, 16 eyes. After surgery, no significant differences between groups were observed in uncorrected distant, intermediate and near visual acuity (p >.46). There were statistically significant differences between-group differences in several levels of defocus corresponding to intermediate vision based on defocus curves (p<.042). There were no significant differences in postoperative contrast sensitivity, internal aberration, and patient satisfaction between groups (p >.36).

Conclusions:

Both IOL models restored distance, intermediate and near visual function and IOL with +2.75D add power more improved intermediate vision.

Financial Disclosure:

NONE

Back to previous